{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:54:10Z","timestamp":1762458850501,"version":"3.41.2"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1111\/igc.0b013e3181a1c7aa","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:30:18Z","timestamp":1291383018000},"page":"361-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Epithelial Ovarian Cancer:"],"prefix":"10.1016","volume":"19","author":[{"given":"J.S.","family":"Tanguay MBCHB","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0005","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.1995.13.7.1584","article-title":"Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer","volume":"13","author":"Kavanagh","year":"1995","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","article-title":"Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients","volume":"12","author":"Coleman","year":"2007","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ijgc-00009577-200705000-00006","article-title":"Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy","volume":"17","author":"Sabbatini","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0025","unstructured":"National Institute for Health and Clinical Excellence Guidance. TA91 Ovarian cancer (advanced)Vpaclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review): guidance, 25 May 2005. (http:\/\/www.nice.org.uk\/TA091)."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0030","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2006.02.026","article-title":"Ca125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan","volume":"103","author":"Gossner","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.bjc.6601501","article-title":"Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?","volume":"90","author":"Gronlund","year":"2004","journal-title":"Br J Cancer."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0045","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1038\/sj.onc.1207008","article-title":"Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression","volume":"22","author":"Leticia","year":"2003","journal-title":"Oncogene."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0055","unstructured":"Deleted in proof."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0060","unstructured":"Deleted in proof."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0065","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-04-3550","article-title":"B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer","volume":"66","author":"Simon","year":"2006","journal-title":"Cancer Res"},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0009-8981(01)00401-6","article-title":"Human kallikrein 10: a novel tumor marker for ovarian carcinoma","volume":"306","author":"Luo","year":"2001","journal-title":"Clin Chim Acta."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0075","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/jco.2008.26.15_suppl.5533","article-title":"Differential expression of CA125 and a novel serum tumor marker HE4 in epithelial ovarian cancer","volume":"26","author":"Brown","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0085","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1c7aa_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000108592","article-title":"Extending the platinum free interval with a non platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the Socrates Retrospective Study","volume":"71","author":"Pignata","year":"2006","journal-title":"Oncology."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181a1c7aa","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181a1c7aa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:07:53Z","timestamp":1753232873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24026999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1048891X24026999"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181a1c7aa","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epithelial Ovarian Cancer:","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181a1c7aa","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 IGCS and ESGO","name":"copyright","label":"Copyright"}]}}